Literature DB >> 9770644

Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

P A Boyer1, P Skolnick, L H Fossom.   

Abstract

Chronic administration of antidepressants produces region-specific adaptive changes in the radioligand binding properties of N-methyl-D-aspartate (NMDA) receptors. We hypothesized that this effect of chronic antidepressant administration was owing to an alteration in NMDA receptor subunit composition. This hypothesis was examined using in situ hybridization with [35S]-labeled riboprobes to quantify the impact of chronic (16 d) injection with either imipramine (15 mg/kg) or citalopram (20 mg/kg) on the levels of transcripts encoding NMDA receptor subunits in mouse brain. These antidepressants altered the levels of mRNA encoding the zeta-subunit in a parallel fashion, with both drugs either reducing transcript levels (e.g., in the cortex, cerebellum, thalamus, and striatum) or producing no substantial effects (e.g., hippocampus). In contrast, these antidepressants often produced distinct, region-specific effects on mRNA levels encoding the epsilon family of subunits. For example, citalopram treatment produced widespread reductions in epsilon 1-subunit mRNA levels (e.g., in frontal cortex, CA2 of hippocampus, and amygdala), whereas imipramine reduced levels of this transcript only in the amygdala. Conversely, imipramine treatment produced widespread reductions in epsilon 2-subunit mRNA levels (e.g., in cortex, CA1-4 of hippocampus, and amygdala), whereas the effects of citalopram on levels of this transcript were largely restricted to amygdala. These findings indicate that long-term antidepressant treatment produces region-specific changes in expression of transcripts for NMDA receptor subunits, presumably altering NMDA receptor composition. Because subunit composition determines the physiological and pharmacological properties of NMDA receptors, these changes may play a critical role in the therapeutic actions of structurally diverse antidepressants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770644     DOI: 10.1007/BF02761776

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  40 in total

1.  A novel treatment of global cerebral ischaemia with a glycine partial agonist.

Authors:  D K Von Lubitz; R C Lin; R J McKenzie; T M Devlin; R T McCabe; P Skolnick
Journal:  Eur J Pharmacol       Date:  1992-08-14       Impact factor: 4.432

2.  Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain.

Authors:  J Vetulani; F Sulser
Journal:  Nature       Date:  1975-10-09       Impact factor: 49.962

3.  Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment.

Authors:  G Nowak; Y Li; I A Paul
Journal:  Eur J Pharmacol       Date:  1996-01-04       Impact factor: 4.432

4.  Delayed biochemical changes following antidepressant treatment.

Authors:  M F Sugrue
Journal:  Psychopharmacol Bull       Date:  1985

5.  Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits.

Authors:  T Ishii; K Moriyoshi; H Sugihara; K Sakurada; H Kadotani; M Yokoi; C Akazawa; R Shigemoto; N Mizuno; M Masu
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

6.  Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain.

Authors:  M Watanabe; Y Inoue; K Sakimura; M Mishina
Journal:  J Comp Neurol       Date:  1993-12-15       Impact factor: 3.215

7.  Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid.

Authors:  G Nowak; R Trullas; R T Layer; P Skolnick; I A Paul
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

8.  Chronic administration of a glycine partial agonist alters the expression of N-methyl-D-aspartate receptor subunit mRNAs.

Authors:  S Bovetto; P Boyer; P Skolnick; L H Fossom
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

9.  Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression.

Authors:  M Papp; E Moryl
Journal:  Eur J Pharmacol       Date:  1994-09-22       Impact factor: 4.432

10.  N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents.

Authors:  D R Lynch; N J Anegawa; T Verdoorn; D B Pritchett
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

View more
  33 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  NMDARs mediate the role of monoamine oxidase A in pathological aggression.

Authors:  Marco Bortolato; Sean C Godar; Miriam Melis; Alessio Soggiu; Paola Roncada; Angelo Casu; Giovanna Flore; Kevin Chen; Roberto Frau; Andrea Urbani; M Paola Castelli; Paola Devoto; Jean C Shih
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

Review 3.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

Review 4.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

5.  Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model.

Authors:  Nigar Yilmaz; Arif Demirdas; Mustafa Yilmaz; Recep Sutcu; Aynur Kirbas; Medine Cumhur Cure; Ibrahim Eren
Journal:  J Membr Biol       Date:  2011-07-14       Impact factor: 1.843

Review 6.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

7.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.

Authors:  Anteneh M Feyissa; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-25       Impact factor: 5.067

Review 8.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

9.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.